Items where Author is "Leyland, Rebecca"

HUDSON, Katie, CROSS, Neil, JORDAN-MAHY, Nicola and LEYLAND, Rebecca (2021). Investigating the tumour-intrinsic role of programmed death-ligand 1 in 2D and 3D cell culture models of human breast cancer. In: British Society for Immunology Congress 2021, Edinburgh, UK, 28 Nov - 01 Dec 2021. (Unpublished) [Conference or Workshop Item]

HARPER, James, BURKE, Shannon, TRAVERS, Jon, RATH, Nicola, LEINSTER, Andrew, NAVARRO, Christel, FRANKS, Ruth, LEYLAND, Rebecca, MULGREW, Kathy, MCGLINCHEY, Kelly, BROWN, Lee, DOVEDI, Simon J., KOOPMANN, Jens-Oliver, DURHAM, Nicholas M., CHENG, Xing, JIN, Hong, EYLES, Jim, WILKINSON, Robert W. and CARROLL, Danielle (2021). Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity. Molecular Cancer Therapeutics. [Article]

HUDSON, Katie, CROSS, Neil, JORDAN-MAHY, Nikki and LEYLAND, Rebecca (2020). The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Frontiers in Immunology, 11, p. 568931. [Article]

HUDSON, Katie, CROSS, Neil, JORDAN-MAHY, Nicola and LEYLAND, Rebecca (2020). Blockade of Programmed Death-Ligand 1 with Atezolizumab in Human Breast Cancer 3D Spheroid Colonies Induces Changes in Cell Viability. In: EACR-AACR-ASPIC Conference: Tumour Microenvironment, Lisbon, Portugal, 02-04 Mar 2020. European Association for Cancer Research. (Unpublished) [Conference or Workshop Item]

HUDSON, Katie, JORDAN-MAHY, Nikki, CROSS, Neil and LEYLAND, Rebecca (2019). Programmed death-ligand 1 expression in human cancer cell lines in two-dimensional and three-dimensional cell culture systems. In: BACR: Tumour Microenvironment meeting, Nottingham, UK, 01-03 Jul 2019. British Association for Cancer Research. (Unpublished) [Conference or Workshop Item]

ARBORE, Giuseppina, HENLEY, Tom, BIGGINS, Laura, ANDREWS, Simon, VIGORITO, Elena, TURNER, Martin and LEYLAND, Rebecca (2019). MicroRNA-155 is essential for the optimal proliferation and survival of plasmablast B cells. Life Science Alliance, 2 (3), e201800244. [Article]

STOKES, Hannah, CROSS, Neil and LEYLAND, Rebecca (2018). Characterisation of novel lung cancer cell lines for immuno-inhibitory markers. In: BMRC/MERI Winter Poster Event 2018, Sheffield, 14 Dec 2018. BMRC/MERI. (Unpublished) [Conference or Workshop Item]

HUDSON, Katie, CROSS, Neil, JORDAN-MAHY, Nicola and LEYLAND, Rebecca (2018). Flow cytometric phenotyping of diverse human cancer cell lines for immunological biomarkers expression. In: BMRC/MERI Winter Poster Event, Sheffield, 14 Dec 2018. BMRC/MERI. (Unpublished) [Conference or Workshop Item]

LEYLAND, Rebecca, ARBORE, Giuseppina, HENLEY, Tom, ANDREWS, Simon, TURNER, Martin and VIGORITO, Elena (2018). miR-155 is essential for proliferation and survival of plasmablast B-cells. In: European Congress for Immunology 2018, Amsterdam, Netherlands, 2-5 September 2018. (Unpublished) [Conference or Workshop Item]

LEYLAND, Rebecca, ABERDEIN, Nicola, WRIGHT, Rebecca and BUTTON, Mary L (2018). Providing productive feedback to Higher Education students. In: SHU Annual Learning and Teaching Conference, Sheffield, UK, 10-11 July 2018. (Unpublished) [Conference or Workshop Item]

OWENS, Kyle, PEAKE, Nicholas, JORDAN-MAHY, Nikki and LEYLAND, Rebecca (2018). Exploring the interactions of Interferon-gamma and polyphenols in colorectal cancer cells. In: British Society for Immunology: Yorkshire Immunology Group Annual Symposium 2018, University of York, UK, 15th June 2018. (Unpublished) [Conference or Workshop Item]

DOWLING, Joshua, FERRIERA DE MATOS, Cristiana, LEYLAND, Rebecca and CROSS, Neil (2018). Investigation of TRAIL resistance in lung cancer cell lines. In: British Society for Immunology: Yorkshire Immunology Group Symposium 2018, University of York, UK, 15th June 2018. (Unpublished) [Conference or Workshop Item]

SHEPPARD, Emily C, MORRISH, Rikke Brandstrup, DILLON, Michael J, LEYLAND, Rebecca and CHAHWAN, Richard (2018). Epigenomic modifications mediating antibody maturation. Frontiers in immunology, 9, p. 355. [Article]

LEYLAND, Rebecca, WATKINS, A., MULGREW, K.A., HOLOWECKYJ, N., BAMBER, L., TIGUE, N.J., OFFER, E., ANDREWS, J., YAN, L., MULLINS, S., OBERST, M.D., ULRICHSEN, J.C., LEINSTER, D.A., MCGLINCHEY, K., YOUNG, L., MORROW, M., HAMMOND, S.A., MALLINDER, P., HERATH, A., CHING LEOW, C., WILKINSON, R.W. and STEWART, R. (2017). A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy that Is Further Enhanced in Combination with an OX40 Agonist. Clinical Cancer Research, 23 (13), 3416-3427. [Article]

MORROW, Michelle, LEYLAND, Rebecca, HAIR, James, STEWART, Ross, TIGUE, Natalie, BAMBER, Lisa, IRELAND, Samantha, HOLOWECKYI, Nicholas, OBERST, Michael, WATKINS, Amanda, OFFER, Emily, PEREZ-MARTINEZ, David, LEOW, Ching Ching, YOUNG, Lesley, VAUGHAN, Tristan, MALLINDER, Philip and WILKINSON, Robert (2017). MEDI1873, a GITR ligand fusion protein (GITRL FP), induces effector T-cell proliferation, modulates T-regulatory cell function and has the potential to combine with checkpoint inhibitors. Cancer Research, 77 (13 Sup), p. 4604. [Article]

LEYLAND, Rebecca and FOSTER, Jennifer (2017). Pharma Industry - where innovation impacts lives. Express Pharma News Bureau. [Other]

MOSELY, SIS, PRIME, JE, SAINSON, RCA, KOOPMANN, JO, WANG, DYQ, GREENAWALT, DM, AHDESMAKI, MJ, LEYLAND, Rebecca, MULLINS, S, PACELLI, L, MARCUS, D, ANDERTON, J, WATKINS, A, ULRICHSEN, JC, BROHAWN, P, HIGGS, BW, MCCOURT, M, JONES, H, HARPER, JA, MORROW, M, VALGE-ARCHER, V, STEWART, R, DOVEDI, SJ and WILKINSON, RW (2017). Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunology Research, 5 (1), 29-41. [Article]

WILLIAMS, G.S., MISTRY, B., GUILLARD, S., ULRICHSEN, J.C., SANDERCOCK, A.M., WANG, J., GONZÁLEZ-MUÑOZ, A., PARMENTIER, J., BLACK, C., SODEN, J., FREETH, J., JOVANOVIC, J., LEYLAND, Rebecca, AL-LAMKI, R.S., LEISHMAN, A.J., RUST, S.J., STEWART, R., JERMUTUS, L., BRADLEY, J.R., BEDIAN, V., VALGE-ARCHER, V., MINTER, R. and WILKINSON, R.W. (2016). Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget, 7 (42), 68278-68291. [Article]

PRIME, John E, MOSELY, Suzanne, KOOPMANN, Jens-Oliver, WANG, Dennis YQ, GREENAWALT, Danielle, HARPER, James, AHDESMAKI, Miika J, LEYLAND, Rebecca, HARRIS, Olivia, STEWART, Ross, BROHAWN, Philip, HIGGS, Brandon, LANGFORD, Bryony, HERATH, Athula, KOZARSKI, Robert, COATES-ULRICHSEN, Jane, ANDERTON, Judith, MORROW, Michelle, SAINSON, Richard CA and WILKINSON, Robert W (2016). Abstract 4186: syngenomic fingerprint: the biomic characterization of the mouse syngeneic tumor models. Cancer Research, 76 (14 Sup), p. 4186. [Article]

STEWART, Ross A, TIGUE, Natalie, IRELAND, Samantha, HAIR, James, BAMBER, Lisa, OBERST, Michael, LEYLAND, Rebecca, WATKINS, Amanda, KENNEDY, Maureen, JENNIFER, Cann, YOUNG, Lesley and WILKINSON, Robert W (2016). MED11873: A novel hexameric GITRL fusion protein with potent agonsitic and immunomodulatory activities in preclinical systems (Abstract only). Cancer Research, 76 (14 Sup), p. 561. [Article]

LEYLAND, Rebecca, WATKINS, Amanda, MULGREW, Kathy A, BAMBER, Lisa, TIGUE, Natalie J, DICK, Emily, HOLOWECKYJ, Nick, YOUNG, Lesley, MORROW, Michelle, HAMMOND, Scott A, LEOW, Ching Ching, WILKINSON, Robert W and STEWART, Ross (2016). A mouse GITRL fusion protein drives T-cell activation and antitumor activity in preclinical mouse models of cancer (Abstract only). Cancer Research, 76 (14 Sup), p. 4902. [Article]

LU, D., NAKAGAWA, R., LAZZARO, S., STAUDACHER, P., ABREU-GOODGER, C., HENLEY, T., BOIANI, S, LEYLAND, Rebecca, GALLOWAY, A., ANDREWS, S., BUTCHER, G., NUTT, S.L., TURNER, M. and VIGORITO, E. (2014). The miR-155-PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation. Journal of Experimental Medicine, 211 (11), 2183-2198. [Article]